Finch Therapeutics Group (NASDAQ:FNCH) Trading Down 2.7% – Should You Sell?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) shares traded down 2.7% during trading on Wednesday . The company traded as low as $12.50 and last traded at $12.50. 283 shares were traded during mid-day trading, a decline of 82% from the average session volume of 1,590 shares. The stock had previously closed at $12.85.

Finch Therapeutics Group Stock Performance

The firm has a fifty day simple moving average of $13.45 and a 200-day simple moving average of $13.23. The company has a market capitalization of $19.32 million, a PE ratio of -1.36 and a beta of 1.18.

About Finch Therapeutics Group

Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.

Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts.